Transcatheter Embolization and Occlusion Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

Transcatheter Embolization and Occlusion Devices Market Summary

• The global transcatheter embolization and occlusion devices market is expected to increase from USD 5,142.20 million in 2024 to USD 10,425.92 million by 2032, reflecting strong and sustained growth.
• The global transcatheter embolization and occlusion devices market is growing at a CAGR of 9.33% during the forecast period from 2025 to 2032.
• The global transcatheter embolization and occlusion devices market is driven by the rising prevalence of chronic disorders such as cancer, vascular malformations, and respiratory diseases, the growing preference for minimally invasive procedures, and the integration of advanced imaging and navigation systems for improved procedural accuracy.
• The leading companies operating in the transcatheter embolization and occlusion devices market include Boston Scientific Corporation, Medtronic, Penumbra, Inc., Cook, Edwards Lifesciences Corporation, Merit Medical Systems, Inc., Johnson & Johnson Services, Inc., Lepu Medical Technology(Beijing) Co., Ltd, Kaneka Medix Corporation, Stryker, phenox GmbH, Braile Biomedica, Terumo Corporation, MicroPort Scientific Corporation, W. L. Gore & Associates, Inc., and others.
• The North America transcatheter embolization and occlusion devices market is driven by the high prevalence of respiratory disorders, including COPD and cancer, along with associated risk factors. Market growth is further supported by the adoption of advanced medical technologies, robust regulatory frameworks, and increasing use of minimally invasive procedures such as bronchial artery embolization and transcatheter arterial chemoembolization, reinforcing the region's strong position globally.
• In the type segment of the transcatheter embolization and occlusion devices market, the resting Non-Coiled category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of the Transcatheter Embolization and Occlusion Devices Market

• Increasing cases of various chronic disorders around the globe are leading to a surge in the transcatheter embolization and occlusion devices market: The growth of the transcatheter embolization and occlusion devices market is significantly fueled by the rising incidence of chronic disorders, including cancer, vascular malformations, pulmonary hemorrhage, and other life-threatening conditions. As the prevalence of these diseases increases globally, there is a heightened need for effective and targeted interventions to manage complications such as uncontrolled bleeding or tumor vascularization. Transcatheter embolization and occlusion devices provide a minimally invasive, precise, and reliable approach to treat these conditions, driving their demand across hospitals, oncology centers, and specialized clinics.
• Rising preference for minimally invasive procedures: Patients and healthcare providers are increasingly favoring minimally invasive procedures due to their multiple advantages over traditional surgery. These procedures reduce surgical trauma, minimize the risk of complications, shorten hospital stays, and allow faster recovery, making them particularly appealing for high-risk or elderly patients. Transcatheter embolization and occlusion devices align perfectly with this trend, enabling precise occlusion of targeted blood vessels without the need for open surgery, which is accelerating their adoption in clinical practice.
• Integration with advanced imaging and navigation systems: Technological advancements, such as real-time fluoroscopy, 3D imaging, and AI-assisted catheter navigation, are enhancing the precision, safety, and efficiency of transcatheter embolization procedures. Integration with these advanced imaging and navigation systems allows clinicians to accurately target affected vessels, monitor device deployment, and reduce procedural complications. This capability not only improves treatment outcomes but also increases the confidence of physicians in performing complex interventions, further supporting the market growth.

Transcatheter Embolization and Occlusion Devices Market Report Segmentation

This transcatheter embolization and occlusion devices market report offers a comprehensive overview of the global transcatheter embolization and occlusion devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation Transcatheter Embolization and Occlusion Devices Market by Type (Coiled [Pushable Coils, Detachable Coils], Non-Coiled [Flow Diverting Devices, Embolization Particles, Liquid Embolic, Others]), Application (Peripheral Vascular Disease, Oncology, Neurology, Urology, Others), End-Users (Hospitals & Clinics, Ambulatory Surgical Centers, and others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing transcatheter embolization and occlusion devices market.

Transcatheter embolization and occlusion devices are minimally invasive medical tools used to block or reduce blood flow in targeted blood vessels for therapeutic purposes. These devices, which include coils, plugs, microspheres, and liquid embolic agents, are commonly employed in the treatment of vascular malformations, tumors, and hemorrhages, as well as in oncological procedures like transcatheter arterial chemoembolization (TACE). By enabling precise and controlled occlusion, they help manage conditions such as pulmonary bleeding, liver and kidney tumors, and uterine fibroids, offering effective treatment while minimizing surgical risks and recovery time.

The Transcatheter Embolization and Occlusion Devices market is witnessing strong growth, fueled by the rising incidence of various chronic disorders such as cancer, vascular malformations, and respiratory complications, which require precise and targeted vascular interventions. This growth is further reinforced by the increasing preference for minimally invasive procedures, as patients and healthcare providers seek treatments that reduce surgical risks, shorten hospital stays, and enable faster recovery. At the same time, the integration of advanced imaging and navigation systems, including real-time fluoroscopy, 3D imaging, and AI-assisted catheter guidance, is enhancing procedural accuracy and safety, making these devices more effective for complex interventions. Together, these factors are expanding the adoption of transcatheter embolization and occlusion devices across hospitals, oncology centers, and specialized clinics, positioning them as essential tools in managing chronic and life-threatening conditions while improving patient outcomes and procedural efficiency.

What are the latest Transcatheter Embolization and Occlusion Devices Market Dynamics and Trends?

The transcatheter embolization and occlusion devices market is witnessing strong and sustained growth, propelled by several interrelated factors. A significant driver is the rising prevalence of chronic disorders, particularly cancer, vascular malformations, and pulmonary hemorrhage, which has created a growing need for precise and effective vascular interventions.

According to DelveInsight 2024, in 2022, approximately 50% of the global cancer patient population was in Asia, 23% in Europe, and nearly 15% in North America. Projections indicate that by 2045, around 32.5 million individuals worldwide are expected to be diagnosed with cancer, further expanding the demand for targeted interventional procedures.

This increasing clinical need is complemented by a growing preference for minimally invasive treatments, which offer substantial benefits including reduced surgical risks, shorter hospital stays, and faster recovery, making them highly appealing to both patients and healthcare providers. In parallel, advancements in imaging and navigation technologies, such as real-time fluoroscopy, three-dimensional imaging, and AI-assisted catheter guidance, are enhancing procedural precision and safety. These innovations allow clinicians to perform complex interventions with greater confidence and improved outcomes.

Together, the convergence of rising disease prevalence, patient preference for minimally invasive approaches, and technological advancements is driving the widespread adoption of transcatheter embolization and occlusion devices across hospitals, oncology centers, and specialized clinics, establishing these devices as indispensable tools in modern interventional care.

Despite the growing adoption of transcatheter embolization and occlusion devices, the market faces several challenges that could limit its expansion. One major concern is the risk of procedural complications, including infections or inadvertent damage to blood vessels, which can lead to extended recovery times or additional interventions. Another critical limitation is the requirement for highly skilled and experienced physicians to perform these minimally invasive procedures, as the success and safety of the treatment heavily depend on operator expertise. Together, these factors create barriers to widespread adoption, influencing clinical decision-making and shaping the competitive dynamics of the transcatheter embolization and occlusion devices market.

Transcatheter Embolization and Occlusion Devices Market Segment Analysis

Transcatheter Embolization and Occlusion Devices Market by Type (Coiled [Pushable Coils, Detachable Coils], Non-Coiled [Flow Diverting Devices, Embolization Particles, Liquid Embolic, Others]), Application (Peripheral Vascular Disease, Oncology, Neurology, Urology, Others), End-Users (Hospitals & Clinics, Ambulatory Surgical Centers, and others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

By Type: Non-Coiled Dominates the Market

The non-coiled category is the dominant force in the transcatheter embolization and occlusion devices market. In 2024, non-coiled accounted for a significant share of approximately 51%. This is driven by its versatility and effectiveness in treating a wide range of vascular and oncological conditions. Unlike traditional coils, non-coiled devices such as plugs, microspheres, and liquid embolic agents offer precise vascular occlusion with predictable deployment, making them particularly useful for treating larger vessels, high-flow vascular malformations, and complex tumors. Devices like the Amplatzer Vascular Plug (Medtronic), Micro Vascular Plug (Medtronic), and Embozene Microspheres (Boston Scientific) are widely adopted due to their reliability, ease of use, and compatibility with minimally invasive procedures.

Non-coiled devices are especially preferred in procedures such as transcatheter arterial chemoembolization (TACE), uterine artery embolization, and management of gastrointestinal or pulmonary hemorrhage. Their design allows for controlled delivery of embolic material, reducing the risk of migration and improving procedural safety. The increasing adoption of these devices is further supported by technological advancements, such as bioresorbable plugs and drug-eluting microspheres, which enhance therapeutic efficacy while minimizing complications. Hospitals and oncology centers are increasingly incorporating non-coiled devices into their interventional radiology protocols due to their precision, efficiency, and suitability for both adult and pediatric patients.

Thus, the non-coiled segment is emerging as a crucial driver of market expansion, offering clinicians enhanced procedural flexibility and improved patient outcomes across a wide spectrum of vascular and oncological interventions.

By Application: Oncology Dominates the Market

The oncology category is the dominant force in the transcatheter embolization and occlusion devices market. In 2024, oncology accounted for a significant share of approximately 45%. This is due to the rising global burden of cancer and the increasing reliance on minimally invasive, targeted treatment modalities. Transcatheter embolization devices are integral to procedures such as transcatheter arterial chemoembolization (TACE), which is widely used to treat primary and metastatic liver cancers, as well as other solid tumors. In TACE, these devices enable the precise delivery of chemotherapeutic agents directly to the tumor site while simultaneously occluding the tumor's blood supply, thereby maximizing local efficacy and minimizing systemic toxicity.

The growing prevalence of liver, lung, renal, and pancreatic cancers has amplified the clinical demand for such procedures, as conventional surgical options are often limited due to tumor location, patient comorbidities, or advanced disease stages. Transcatheter embolization and occlusion devices also play a crucial role in managing cancer-related complications, including tumor hemorrhage, which can be life-threatening if not promptly controlled.

In addition, oncology centers and hospitals are increasingly investing in advanced interventional radiology infrastructure, such as high-resolution imaging systems and catheterization labs, to facilitate these procedures. The adoption of newer embolic materials, including drug-eluting beads and bioresorbable agents, has further enhanced procedural safety and treatment outcomes, encouraging wider use of these devices in oncological care.

Furthermore, patient and physician awareness of minimally invasive cancer therapies is growing, as these approaches often reduce hospital stays, enable faster recovery, and provide targeted therapy for inoperable tumors. This combination of rising cancer incidence, technological advancements, and increasing adoption of minimally invasive interventions positions the oncology segment as a significant driver of expansion in the transcatheter embolization and occlusion devices market, contributing substantially to overall market growth.

By End-Users: Hospital & Clinics Dominate the Market

Hospitals and clinics hold the largest share in the end-user segment of the transcatheter embolization and occlusion devices market due to their comprehensive infrastructure, availability of specialized interventional radiology departments, and access to highly skilled healthcare professionals. These facilities are equipped to perform complex minimally invasive procedures such as bronchial artery embolization and transcatheter arterial chemoembolization (TACE), which require advanced imaging systems, catheterization labs, and post-procedure monitoring capabilities.

Additionally, hospitals and clinics often serve as referral centers for severe and complicated cases, including advanced respiratory disorders, vascular malformations, and cancer, where embolization procedures are critical for patient management. The high patient throughput, combined with the ability to provide integrated care and follow-up, makes hospitals and clinics the preferred setting for the use of these devices, thereby securing their dominant position in the market.

Transcatheter Embolization and Occlusion Devices Market Regional Analysis

North America Transcatheter Embolization and Occlusion Devices Market Trends

North America, led by the United States, dominates the global transcatheter embolization and occlusion devices market, accounting for approximately 39% of the total market share in 2024. The growth of the transcatheter embolization and occlusion devices market in the United States is largely driven by a substantial patient population suffering from respiratory disorders such as COPD and cancer, often accompanied by associated risk factors. The widespread adoption of advanced medical technologies, supported by robust regulatory frameworks in the region, further strengthens market expansion.

According to a 2024 analysis by DelveInsight, approximately 11.5 million people in the US are living with chronic respiratory disorders, which progressively impair lung function and breathing. The analyst also indicates that around 14.5 million individuals were affected by COPD. Transcatheter embolization and occlusion devices play a critical role in managing severe pulmonary hemorrhage, a life-threatening complication commonly observed in advanced respiratory conditions. Bronchial artery embolization, performed using these devices, offers a minimally invasive and highly effective approach to controlling lung bleeding, thereby driving their demand.

In addition, cancer prevalence in the US is rising sharply. By the end of 2024, an estimated 3 million new cancer cases are expected to be diagnosed, including approximately 14,910 cases among adolescents aged 13 to 19. According to analysis, the US accounted for 89.1% of all cancer cases in the region, while Canada represented 10.9% in 2022. Transcatheter embolization and occlusion devices are indispensable in various oncological interventions, including transcatheter arterial chemoembolization (TACE), which enables targeted delivery of chemotherapy while simultaneously blocking tumor blood supply. The rising incidence of cancer is therefore significantly boosting market demand.

Thus, the combined impact of a large respiratory disorder patient pool, increasing cancer prevalence, and strong adoption of advanced medical technologies creates a highly favorable growth environment for the transcatheter embolization and occlusion devices market in North America.

Europe Transcatheter Embolization and Occlusion Devices Market Trends

The European Transcatheter Embolization and Occlusion Devices market is witnessing steady growth, driven by a combination of clinical, technological, and demographic factors. The increasing prevalence of conditions such as cancer, vascular malformations, and uterine fibroids is driving demand, as embolization therapies provide effective and minimally invasive treatment options. Technological advancements in embolic materials, including bioresorbable agents and drug-eluting technologies, are enhancing the safety and efficacy of procedures, building confidence among healthcare providers and patients.

Additionally, the expansion of interventional radiology capabilities and improvements in healthcare infrastructure are improving access to these advanced devices across the region. Among European countries, Germany, France, and the United Kingdom are expected to lead market growth, supported by advanced healthcare systems, high patient awareness, and increasing adoption of minimally invasive interventions. Therefore, Europe is emerging as a key growth region in the global transcatheter embolization and occlusion devices market, driven by rising clinical demand, innovation, and strengthened healthcare infrastructure.

Asia-Pacific Transcatheter Embolization and Occlusion Devices Market Trends

The Asia-Pacific transcatheter embolization and occlusion devices market is witnessing rapid expansion, reflecting a robust CAGR of 10.76% during the forecast period from 2025 to 2032. The Asia-Pacific transcatheter embolization and occlusion devices market is witnessing significant growth, driven by a combination of demographic, clinical, and technological factors. The rising prevalence of cancer, particularly liver and lung cancers, is fueling demand, as embolization therapies offer effective and minimally invasive treatment options. Technological advancements in device design and procedural techniques are enhancing the safety and effectiveness of embolization procedures, building confidence among healthcare providers and patients.

Additionally, increased healthcare investments and improvements in medical infrastructure are expanding access to advanced embolization and occlusion devices, particularly in emerging markets. Among countries in the region, Japan is expected to experience the highest growth, supported by improved patient awareness, advanced diagnostic capabilities, and a strong focus on clinical outcomes and cost-effectiveness. Overall, the Asia-Pacific market is emerging as a key growth area in the global transcatheter embolization and occlusion devices landscape, driven by rising demand, innovation, and strengthened healthcare infrastructure.

Who are the major players in the Transcatheter Embolization and Occlusion Devices Market?

The following are the leading companies in the Transcatheter Embolization and Occlusion Devices market. These companies collectively hold the largest market share and dictate industry trends.

• Boston Scientific Corporation
• Medtronic
• Penumbra, Inc.
• Cook
• Edwards Lifesciences Corporation
• Merit Medical Systems, Inc.
• Johnson & Johnson Services, Inc.
• Lepu Medical Technology(Beijing)Co., Ltd
• Kaneka Medix Corporation
• Stryker
• phenox GmbH
• Braile Biomedica
• Terumo Corporation
• MicroPort Scientific Corporation
• W. L. Gore & Associates, Inc.

How is the competitive landscape shaping the Transcatheter Embolization and Occlusion Devices Market?

The competitive landscape of the transcatheter embolization and occlusion devices market is moderately consolidated, with a few key players such as Boston Scientific, Medtronic, Terumo, and Penumbra dominating a significant share of the market. These companies are driving growth through continuous innovation, strategic partnerships, and expansion of their product portfolios. They are investing heavily in research and development to introduce advanced embolization and occlusion devices that provide higher precision, improved safety, and minimally invasive solutions. Collaborations and acquisitions are further shaping market dynamics, enabling integration of AI-assisted procedural planning, imaging-guided delivery systems, and bioresorbable materials.

Emerging players are also entering the market, leveraging niche technologies and cost-effective solutions to capture smaller segments. Intense competition exists not only in product development but also in regional expansion, patient outcome improvement, and addressing procedural challenges. Regulatory approvals, device recalls, and supply chain efficiency remain crucial factors influencing market positioning, making technological differentiation and agility essential for sustaining growth in this moderately consolidated market.

Transcatheter Embolization and Occlusion Devices Market Segmentation

• Transcatheter Embolization and Occlusion Devices by Type Exposure
• Coiled
• Pushable Coils
• Detachable Coils
• Non-Coiled
• Flow Diverting Devices
• Embolization Particles
• Liquid Embolic
• Others
• Transcatheter Embolization and Occlusion Devices by Application Exposure
• Peripheral Vascular Disease
• Oncology
• Neurology
• Urology
• Others
• Transcatheter Embolization and Occlusion Devices End-Users Exposure
• Hospital & Clinics
• Ambulatory Surgical Centers
• Others
• Transcatheter Embolization and Occlusion Devices Geography Exposure
• North America Transcatheter Embolization and Occlusion Devices Market
• United States Transcatheter Embolization and Occlusion Devices Market
• Canada Transcatheter Embolization and Occlusion Devices Market
• Mexico Transcatheter Embolization and Occlusion Devices Market
• Europe Transcatheter Embolization and Occlusion Devices Market
• United Kingdom Transcatheter Embolization and Occlusion Devices Market
• Germany Transcatheter Embolization and Occlusion Devices Market
• France Transcatheter Embolization and Occlusion Devices Market
• Italy Transcatheter Embolization and Occlusion Devices Market
• Spain Transcatheter Embolization and Occlusion Devices Market
• Rest of Europe Transcatheter Embolization and Occlusion Devices Market
• Asia-Pacific Transcatheter Embolization and Occlusion Devices Market
• China Transcatheter Embolization and Occlusion Devices Market
• Japan Transcatheter Embolization and Occlusion Devices Market
• India Transcatheter Embolization and Occlusion Devices Market
• Australia Transcatheter Embolization and Occlusion Devices Market
• South Korea Transcatheter Embolization and Occlusion Devices Market
• Rest of Asia-Pacific Transcatheter Embolization and Occlusion Devices Market
• Rest of the World Transcatheter Embolization and Occlusion Devices Market
• South America Transcatheter Embolization and Occlusion Devices Market
• Middle East Transcatheter Embolization and Occlusion Devices Market
• Africa Transcatheter Embolization and Occlusion Devices Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are rapidly transforming the healthcare landscape, particularly in the development and application of medical devices. By integrating advanced machine learning algorithms and data analytics, AI enables real-time monitoring, predictive diagnostics, and personalized treatment strategies. In the context of medical devices, AI is enhancing the precision and efficiency of procedures, such as transcatheter interventions, remote patient monitoring, and implantable devices. These technologies can analyze vast amounts of patient data to detect early signs of complications, optimize device performance, and guide clinical decision-making with unprecedented accuracy.

Beyond clinical settings, AI is also streamlining operational workflows, improving supply chain management, and reducing the risk of human error. As a result, AI-powered devices not only improve patient outcomes but also contribute to more cost-effective and proactive healthcare delivery, marking a significant leap forward in the integration of technology and medicine.

U.S. Tariff Impact Analysis on the Transcatheter Embolization and Occlusion Devices Market:

The U.S. tariffs on medical devices have created a profound impact on the transcatheter embolization and occlusion devices market, affecting every stage of the supply chain. The increased cost of imported components has forced manufacturers to rethink their production strategies, often resulting in higher prices for healthcare providers. Hospitals and clinics are responding to these pressures by carefully planning their inventories, sometimes purchasing devices in larger quantities to guard against future price increases or delays.

The uncertainty surrounding trade policies has also influenced the financial stability of major companies in the sector, leading to fluctuations in revenue and investment decisions. At the same time, companies are seeking innovative ways to maintain the availability and affordability of these critical devices. Some are investing in domestic manufacturing capabilities, forming strategic partnerships, and optimizing production processes. These efforts not only help mitigate the impact of tariffs but also ensure that patients continue to have access to life-saving interventions for cardiovascular conditions, illustrating how trade policies can ripple across the entire healthcare ecosystem.

How This Analysis Helps Clients

• Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
• Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
• Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
• Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Transcatheter Embolization and Occlusion Devices market report study

• Market size analysis for the current Transcatheter Embolization and Occlusion Devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the Transcatheter Embolization and Occlusion Devices market.
• Various opportunities available for the other competitors in the Transcatheter Embolization and Occlusion Devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current Transcatheter Embolization and Occlusion Devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the Transcatheter Embolization and Occlusion Devices market growth in the future?

Frequently Asked Questions for the Transcatheter Embolization and Occlusion Devices Market

1. What is the growth rate of the transcatheter embolization and occlusion devices market?

• The transcatheter embolization and occlusion devices market is estimated to grow at a CAGR of 9.33% during the forecast period from 2025 to 2032.

2. What is the market for transcatheter embolization and occlusion devices?

• The transcatheter embolization and occlusion devices market was valued at USD 5,142.20 million in 2024, and is expected to reach USD 10,425.92 million by 2032.

3. Which region has the highest share in the transcatheter embolization and occlusion devices market?

• The North America transcatheter embolization and occlusion devices market is driven by the high prevalence of respiratory disorders, including COPD and cancer, along with associated risk factors. Market growth is further supported by the adoption of advanced medical technologies, robust regulatory frameworks, and increasing use of minimally invasive procedures such as bronchial artery embolization and transcatheter arterial chemoembolization, reinforcing the region's strong position globally.

4. What are the drivers for the Transcatheter Embolization and Occlusion Devices market?

• The global transcatheter embolization and occlusion devices market is driven by the rising prevalence of chronic disorders such as cancer, vascular malformations, and respiratory diseases, the growing preference for minimally invasive procedures, and the integration of advanced imaging and navigation systems for improved procedural accuracy.

5. Who are the key players operating in the transcatheter embolization and occlusion devices market?

• Some of the key market players operating in the transcatheter embolization and occlusion devices market include Boston Scientific Corporation, Medtronic, Penumbra, Inc., Cook, Edwards Lifesciences Corporation, Merit Medical Systems, Inc., Johnson & Johnson Services, Inc., Lepu Medical Technology(Beijing) Co., Ltd, Kaneka Medix Corporation, Stryker, phenox GmbH, Braile Biomedica, Terumo Corporation, MicroPort Scientific Corporation, W. L. Gore & Associates, Inc., and Others.